Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130806
2.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34978890
3.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32447500
4.
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
AIDS Behav
; 24(12): 3473-3481, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32410051
5.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-28750935
6.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23830355
7.
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
Br J Clin Pharmacol
; 76(6): 858-67, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-23701202
8.
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
J Acquir Immune Defic Syndr
; 91(2): 157-161, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36094481
9.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Lancet HIV
; 8(11): e668-e678, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34656207
10.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33794181
11.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
12.
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
HIV Res Clin Pract
; 20(4-5): 111-122, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31533539
13.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Lancet Infect Dis
; 15(10): 1145-1155, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26201299
14.
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
BMC Infect Dis
; 3: 10, 2003 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-12795812
15.
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
J Acquir Immune Defic Syndr
; 43(3): 284-92, 2006 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16967040